

## **PROXY/VOTING BY CORRESPONDENCE FORM**

The extraordinary general meeting of Scandion Oncology A/S ("Scandion Oncology" or the "Company") on 28 October 2022, at 11.00 AM (CET) at the Company's address Fruebjergvej 3, DK-2100 Copenhagen, Denmark

I, the undersigned, hereby grant authority by proxy or vote by correspondence at the extraordinary general meeting of Scandion Oncology to be held on **28 October 2022** as set out below:

## Please mark the appropriate box A), B), C), or D). Please note that it is only possible either to grant authority by proxy or to vote by correspondence.

A)  $\Box$  Proxy is given to an identified third person:

Name and address of the proxy holder (CAPITAL LETTERS)

- B) D Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the recommendations of the board of directors as stated in the table below.
- C) D Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions.
- D) D The vote by correspondence is given in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions. The vote by correspondence is irrevocable.

Items on the agenda (the full agenda is included in the notice of the meeting)		FOR	AGAINST	ABSTAIN	The board's recommendation
1.	Election of chairman of the meeting		*		FOR
2.	Election of an additional member to the board of directors A) Nils Brünner		*		FOR
3.	Proposal to authorize the board of directors to issue shares with pre-emptive rights for the Company's existing shareholders				FOR
4.	Proposal to authorize the board of directors to issue shares without pre-emptive rights for the Company's existing shareholders				FOR

\*In connection with the election of persons (election of chairman of the meeting (item 1) and member of the board of directors (item 2), it is legally speaking only possible to vote in <u>favour</u> of the proposed candidates or in <u>favour</u> of alternative candidates proposed for the positions in question. Consequently, the proxy form cannot be used to vote <u>against</u> the proposed candidates.




## A form that has only been dated and signed shall be considered as a proxy given to the board of directors to vote in accordance with the recommendations of the board of directors as they appear in the table above.

The proxy shall apply to all subjects discussed at the extraordinary general meeting. If new proposals are presented and put to the vote, including proposals for amendments, the proxy holder shall be entitled to vote on your behalf in accordance with his or her own convictions.

The proxy/vote by correspondence applies to the number of shares in the possession of the undersigned on the date of registration, 21 October 2022. The shareholding is calculated on the basis of the entry in the Company's register of shareholders and notifications on ownership that the Company has received, but not yet entered in the register of shareholders.

The Company requests that the completed and signed form is received by the Company at the address Fruebjergvej 3, DK-2100 Copenhagen, or by e-mail to: gm@scandiononcology.com no later than 26 October 2022 at 11.59 p.m. (CET).



Signature